Under Cornerstone’s Ownership, Zyflo Asthma Med Repositioned For Growth
This article was originally published in The Pink Sheet Daily
After completing a reverse merger with Critical Therapeutics last year, Cornerstone has retooled the marketing message for the asthma medication and ramped up commercial support.
You may also be interested in...
Cornerstone gains two commercial products for the acute-care hospital setting, Cardene and Retavase, with the acquisition of EKR Therapeutics for $125 million upfront and potential milestones.
Critical had been in line for delisting from NASDAQ; new firm, Cornerstone Therapeutics, will apply to relist.
The company said it will update investors on the path forward for zuranolone in major depressive disorder after finalizing discussions with the US FDA. It would not confirm if a meeting had taken place yet.